Daiichi Sankyo team now part of reconstituted Ranbaxy board
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories, a subsidiary ofDaiichi Sankyo, has reconstituted its board of directors to reflect the company's new ownership structure. Daiichi Sankyo now controls 63.92% of Ranbaxy's equity share capital.